MRNS Market Cap History
Below is a table of the MRNS market cap history going back to 7/31/2014:

Date MRNS Market Cap
7/31/201497.87M
9/12/2014110.60M
11/13/201489.09M
3/12/2015147.82M
5/11/2015112.41M
8/3/2015248.88M
10/29/2015111.96M
3/7/2016116.08M
4/29/2016107.11M
8/8/201628.87M
11/7/201621.68M
3/10/201733.61M
4/28/201732.28M
7/27/201751.11M
10/30/2017229.24M
3/5/2018212.73M
5/1/2018182.34M
8/1/2018284.89M
10/26/2018203.84M
3/11/2019206.92M
4/30/2019259.62M
8/7/201956.26M
11/5/201965.72M
3/12/2020116.19M
5/1/2020173.46M
8/4/2020212.62M
9/23/2020366.89M
11/5/2020413.02M
3/8/2021611.59M
5/14/2021592.73M

Also see: MRNS Shares Outstanding History
and MRNS YTD Return
MRNS Historical Market Cap:
+30.37% CAGR
MRNS Historical Market Cap: +30.37% CAGR

Mouse over chart for data details
7/31/2014 ...5/14/2021
Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare seizure disorders. Co.'s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of gamma-aminobutyric acid (GABAA) being developed in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. Ganaxolone acts at both synaptic and extrasynaptic GABAA receptors and exhibits anti-seizure, antidepressant and anxiolytic properties. We show 30 historical shares outstanding datapoints in our MRNS shares outstanding history coverage, used to compute MRNS market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing MRNS market cap history over the course of time is important for investors interested in comparing MRNS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of MRNS versus a peer is one thing; comparing MRNS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like MRNS can fluctuate over the course of history. With this page we aim to empower investors researching MRNS by allowing them to research the MRNS market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for MRNS:
MRNS SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Marinus Pharmaceuticals (MRNS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

MRSN Market Cap History
MRTX Market Cap History
MSON Market Cap History
MTEM Market Cap History
MYGN Market Cap History
MYL Market Cap History
MYND Market Cap History
MYOK Market Cap History
NAOV Market Cap History
NBIX Market Cap History
More Healthcare companies »

 

MRNS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.